Legend Biotech CEO Ying Huang On Moving Fast In the BCMA CAR-T Race
Chinese Firm Is Partnered With Second Place Contender Janssen In US
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
You may also be interested in...
The US FDA has extended the user fee date by three months for the partners’ BCMA-targeting CAR-T therapy but its first-to-market rival is facing manufacturing challenges that limit access to treatment.
CEO Ying Huang talked about the biotech’s plans for CAR-T therapies after its J&J-partnered program.
Cilta-cel likely will be the second BCMA-targeting CAR-T therapy approved in the US for multiple myeloma, but appears to have an efficacy advantage over BMS/bluebird’s first-to-market Abecma.